Changes and clinical significance of serum galectin-3, fractalkine and soluble suppression of tumorigenicity 2 in patients with dilated cardiomyopathy

Yin Jie; Li Wencheng; Huan Lei; Liu Hongyan; Song Suping

doi:10.3969/j.issn.1674-4055.2021.03.14

Home>Articles>Changes and clinical significance of serum galectin-3, fractalkine and soluble suppression of tumorigenicity 2 in patients with dilated cardiomyopathy

DOI: 10.3969/j.issn.1674-4055.2021.03.14

Changes and clinical significance of serum galectin-3, fractalkine and soluble suppression of tumorigenicity 2 in patients with dilated cardiomyopathy

Yin Jie

Li Wencheng

Huan Lei

Liu Hongyan

Song Suping

Machine-generated Keywords：

Publication Date：2021-03-28

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：4( 318-321 )

Chinese Journal of Evidence-Bases Cardiovascular Medicine

ISTIC

ISSN：1674-4055

Year, Vol.(Issue)：2021,13(3)